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 Dear Sir, 
 
We take note of the comments of Dr Haag on our cross-sectional descriptive observational study on 
self-medication of regular headache in the naturalistic setting of the community pharmacy. Dr Haag 
draws our attention to his publication on evidence-based recommendations for the self-medication 
of migraine and tension-type headache, “addressed to physicians engaged in primary care as well as 
pharmacists and patients“ [1]. He concludes his comments by stating that “improved primary care 
management of headache in pharmacies… could be developed on the basis of the already existing 
data and would not have required this study…”. 
 
We are puzzled as to what existing data Dr Haag is referring to. Indeed, a shortlist of drugs for self-
medication of migraine and tension-type headache has been drafted by Dr Haag and co-authors, but 
there are some data to suggest that guidelines for the management of headache in primary care are 
seldom applied [2] and community pharmacists may represent an underused resource in the 
management of headaches in primary care [3]. We virtually have no data obtained directly in the 
community pharmacy setting.  
 
We also respond to a number of specific remarks that were made in response to our article: 
1) Our target population consisted of individuals presenting for self-medication at a community 
pharmacy and our goal was to formulate recommendations for improved community pharmacy 
management of headache complaints. We did not suggest the data were generalizable to self-
medication in the general population. The random pharmacy selection and the consecutive patient 
recruitment however contributed to the generalizability of our results towards the entire population 
of pharmacy customers self-medicating regular headache, as the sale of OTC analgesics is limited to 
pharmacies in Belgium.  
2) We believe the inclusion rate of 59 % in this study is acceptable. It is similar to response rates in 
other questionnaire studies in (headache) patients, such as the large HUNT-3 study [4]. Potential bias 
caused by those who refused participation could not be assessed as our Ethics Committee prohibits 
data collection in study refusers, but we have recorded raisons for refusal to participate (mainly ‘no 
time’ and ‘no interest’). We had pre-defined that patients for whom other people purchased the 
medication were not eligible for participation.  
3) Due to the lack of other studies in pharmacy customers self-medicating headache, comparison of 
our sample to already published data was not possible. The only reference paper available in 
literature is a study in 22 pharmacy customers with headache [5].  
4) We did not intend to assess the prevalence of medication overuse in the general headache 
population nor among pharmacy customers (and we also do not state this in the paper). The 
objective of our study is clearly stated in the paper: “The present observational community 
pharmacy-based study aimed to investigate the headache characteristics and the medication use of 
persons with regular headache, defined for this study as headache occurring at least once per month, 
presenting for self-medication.” The ultimate goal was to formulate recommendations for improved 
pharmacy management of headache. As extra pharmacist follow-up is specifically warranted for 
those individuals with regular headache complaints, we only included patients with frequent 
headaches (defined for this study as headache ≥1x/month). Pharmacy customers with occasional 
headaches were not within the scope of this study, because in most cases they self-treat successfully 
and are not at risk for developing medication overuse. 
5) Dr Haag states that a substantial proportion of ‘overusers’ in our survey did not have any 
headaches at all, which is a misunderstanding. All participants suffered at least 1x/month from 
headache and used the reported medication for their headaches. However, a substantial proportion 
of medication overusers did not have chronic headache, indicating that they also used the analgesics 
for other pain conditions than headache. We are planning a follow-up study in which this aspect, 
which was unanticipated, will be included. Regarding the definition of medication overuse, we used 
the internationally accepted ICHD-IIR definition [6]. Medication overuse is a prerequisite for 
developing medication-overuse headache (MOH), and it has been suggested that MOH can develop 
in migraine patients using painkillers for another condition [7, 8]. 
6,7) An inherent limitation of a cross-sectional design is that causal relationships cannot be 
determined. Medication overuse does not necessarily lead to MOH, and we did not suggest patients 
suffered from MOH. From a community pharmacist’s point of view, the conceptual difficulties in 
dealing with medication overuse and MOH are irrelevant. The pharmacist’s role is to prevent overuse 
of acute headache medication, in order to avoid development of MOH or chronification of the 
underlying headache condition.  
We hope to have clarified the issues raised by Dr Haag, and our observational data will be useful to 
achieve better implementation of existing guidelines on self-medication of headache into the 
community pharmacy setting . 
Yours sincerely, 
Els Mehuys and Koen Boussery, Pharmaceutical Care Unit, Ghent University, Ghent, Belgium 
Koen Paemeleire, Department of Neurology, Ghent University Hospital, Ghent, Belgium 
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